Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 -221.0%
March 31, 2026 -175.9%
December 31, 2025 -277.2%
September 30, 2025 -169.7%
June 30, 2025 -185.6%
March 31, 2025 -515.1%
December 31, 2024 -189.7%
September 30, 2024 -10.40%
June 30, 2024 -530.0%
March 31, 2024 -600.6%
December 31, 2023 -301.8%
September 30, 2023 -406.5%
June 30, 2023 -257.2%
March 31, 2023 -97.78%
December 31, 2022 -288.6%
September 30, 2022 -205.7%
June 30, 2022 -499.2%
March 31, 2022 -384.3%
December 31, 2021 -1.35K%
September 30, 2021 -247.6%
June 30, 2021 -410.4%
March 31, 2021 -715.5%
December 31, 2020 -566.7%
September 30, 2020 -600.3%
June 30, 2020 -505.7%
Date Value
March 31, 2020 -702.0%
December 31, 2019 -401.3%
September 30, 2019 -373.7%
June 30, 2019 -689.6%
March 31, 2019 -540.4%
December 31, 2018 -74.58%
September 30, 2018 -585.4%
June 30, 2018 -989.8%
March 31, 2018 -1.11K%
December 31, 2017 -871.3%
September 30, 2017 -555.9%
June 30, 2017 -650.7%
March 31, 2017
December 31, 2016 -420.0%
September 30, 2016
June 30, 2016
March 31, 2016 -1.08K%
December 31, 2015 -2.07K%
September 30, 2015
June 30, 2015 -11.04%
March 31, 2015 -9.44%
December 31, 2014 -62.61%
September 30, 2014 -27.67%
June 30, 2014 -54.84%
March 31, 2014 -52.56%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Agenus, Inc. -1.64%
Amgen, Inc. 37.29%
Anika Therapeutics, Inc. 10.15%
BioCryst Pharmaceuticals, Inc. 21.03%
Imunon, Inc. --